企業を読み込み中
Keep exploring
The themes Nurix Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.$48BA+
EXELExelixis, Inc.$17.3BA+
JAZZJazz Pharmaceuticals plc$15.9BA
HALOHalozyme Therapeutics, Inc.$11.6BA+
TECHBIO-Techne Corp$11.4BA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation2026年10月21日CBGraded C, now B
MCKMckesson Corporation2026年11月4日BAGraded B, now A
CVSCVS Health Corp2026年11月4日BAGraded B, now A
EWEdwards Lifesciences Corporation2026年11月4日BAGraded B, now A
BIIBBiogen Inc.2026年10月28日BAGraded B, now A
どうやって稼いでいるか
- Collaboration revenue64%
- License revenue36%
売上構成比はfiscal year ended 2025-11-30, high confidenceの推計であり、提出された報告書の数字ではありません。
競合
何を売っているか4
Bexobrutideg (NX-5948)
An experimental oral medicine designed to make cells remove Bruton tyrosine kinase, a protein involved in some blood cancers. It is being tested in patients with blood cancers, including chronic lymphocytic leukemia.
NX-1607
An experimental oral medicine that blocks CBL-B, a cell protein that restrains immune cells. It is being tested to help immune cells attack tumors.
Zelebrudomide (NX-2127)
An experimental oral medicine designed to remove Bruton tyrosine kinase and two proteins involved in immune-cell activity. Nurix discontinued further clinical development; some patients already receiving it may continue treatment.
NX-0479 / GS-6791
A partner-developed experimental medicine designed to degrade IRAK4, a protein involved in inflammation.
誰が買っているか4
- Gilead pays for research into drug candidates and may license candidates for further development.
- Sanofi pays for research into drug candidates and may license candidates for further development.
- Pfizer pays for research into drug candidates intended for attachment to antibodies and may license them for development.
- Roche licensed bexobrutideg and shares its development and United States commercial responsibilities with Nurix.
何に支えられ、何に崩されうるか
事業が頼っているもの
- 1Nurix has no product-sale revenue and depends on collaboration payments, license payments, and outside financing to fund its work.
- 2It relies on contract manufacturers for drug ingredients and finished medicines used in clinical trials.
- 3It relies on outside organizations to conduct clinical trials and on pharmaceutical partners to develop or sell some licensed drug candidates.
うまくいかなくなる可能性
- 1Nurix’s drug candidates are still being tested in people; trial results, safety findings, patient enrollment, or regulatory decisions could delay or end their development.
- 2Because Nurix has no approved medicines for sale, its income depends on partner payments and licensing events, which can vary in timing and may not recur.
- 3Problems with outside manufacturers or clinical-trial contractors could interrupt drug supply or delay trials.
Nurix Therapeutics, Inc.について
Nurix develops experimental medicines designed to make cells remove disease-related proteins, rather than simply block them. Its discovery system uses machine learning and large chemical libraries to find starting points for drugs. Pharmaceutical partners pay for research and rights to drug candidates; Nurix also develops some candidates itself. It has no approved medicines for sale.
- 本社
- San Francisco, California
- 設立
- 2009 (founding year, medium confidence)
- 上場市場
- Nasdaq Global Select Market
- 決算期
- November 30
Nurix Therapeutics, Inc. 自身が米国証券取引委員会（SEC）に提出した書類にもとづきます。数字は報告されたままで、1 株当たりの履歴は今日の株数基準に修正済みです。 これは事業の説明です——投資助言ではなく、売買を勧めるものでもありません。
